Trial · NCT05252845
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification. | From the date of the first vaccination to 28 days after the last vaccination (up to approximately 1 month) | |
| Primary | Occurrence of Serious Adverse Events (SAEs), According to the MedRA Classification. | During the whole study period, i.e. during a 6-month follow-up period from the receipt of first vaccination | |
| Primary | Occurrence of Solicited Adverse Event Within 7 Days of Each Vaccination | Within 7 days of each vaccination. | |
| Secondary | Number of Participants With Seroconversions in C-Term | at study Month 1 | Number of Participants with Seroconversions in C-Term |
| Secondary | Number of Participants With Seroconversions in C-Term | at study Month 2 | Number of Participants with Seroconversions in C-Term |
| Secondary | Number of Participants With Seroconversions in C-Term | at study Month 3 | Number of Participants with Seroconversions in C-Term |
| Secondary | Number of Participants With Seroconversions in C-Term | at study Month 6 | Number of Participants with Seroconversions in C-Term |
| Secondary | Number of Participants With Seroconversions in NANP | at study Month 1 | Number of Participants with Seroconversions in NANP |
| Secondary | Number of Participants With Seroconversions in NANP | at study Month2 | Number of Participants with Seroconversions in NANP |
| Secondary | Number of Participants With Seroconversions in NANP | at study Month 3 | Number of Participants with Seroconversions in NANP |
| Secondary | Number of Participants With Seroconversions in NANP | at study Month 6 | Number of Participants with Seroconversions in NANP |
| Secondary | Number of Participants With Seroconversions in R21 | at study Month 1 | Number of Participants with Seroconversions in R21 |
| Secondary | Number of Participants With Seroconversions in R21 | at study Month 2 | Number of Participants with Seroconversions in R21 |
| Secondary | Number of Participants With Seroconversions in R21 | at study Month 3 | Number of Participants with Seroconversions in R21 |
| Secondary | Number of Participants With Seroconversions in R21 | at study Month 6 | Number of Participants With Seroconversions in R21 |
| Secondary | Number of Participants With Seroconversions in HBsAg | at study Month 1 | Number of Participants with Seroconversions in HBsAg |
| Secondary | Number of Participants With Seroconversions in HBsAg | at study Month 2 | Number of Participants with Seroconversions in HBsAg |
| Secondary | Number of Participants With Seroconversions in HBsAg | at study Month 3 | Number of Participants with Seroconversions in HBsAg |
| Secondary | Number of Participants With Seroconversions in HBsAg | at study Month 6 | Number of Participants with Seroconversions in HBsAg |
| Secondary | For Arms 1 and 3, Piperaquine Levels Following the Administration of the Antimalarials With or Without Vaccine | Study month 0 | For Arms 1 and 3, Piperaquine levels (Cmax) following the administration of the antimalarials with or without vaccine |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05252845/registered